Anticoagulant Market Synopsis:
Anticoagulant Market Size Was Valued at USD 42.92 Billion in 2023, and is Projected to Reach USD 97.14 Billion by 2032, Growing at a CAGR of 9.50% From 2024-2032.
Anticoagulant means the part of the pharmaceuticals industry that has products that prevent blood clots and help control the clotting factors formulated in the bloodstream. Wolf and the colleagues state that anticoagulants or blood thinners are primarily used to prevent formation of blood clots and to lessen the occurrence of such conditions as stroke, deep vein thrombosis, and pulmonary embolism. These medications function by acting on different steps of clotting and halting an enzyme or reducing platelet’s ability to clot. The scope involves prescription and OTC, DOACs, vitamin K antagonist, and low molecular weight heparins which are used in hospital and other clinics.
Global market of anticoagulants has been growing year on year due to rising incidence of cardiovascular diseases, atrial fibrillation and other thromboembolic conditions that call for prophylactic and curative interventions. With the increase in population, these diseases arise more and more often; stroke, deep vein thrombosis, pulmonary embolism – all these require anticoagulants. The availability of improved forms of anticoagulant drugs and major improvements to non-VKA oral anticoagulation’s, including apixaban, rivaroxaban and dabigatran, are safer, more easily administered and can be used without adherence to strict dietary rules like warfarin have also contributed to the growth of the market. Moreover, earlier identification by not only the public but also healthcare professionals of Thromboembolic dangers increases the use of anticoagulants.
New ideas and studies involving the anticoagulant therapy have led to more specific treatment products with less side effects hence new agents. Additionally, increased focus on technological advances, and updating of delivery systems such as oral anticoagulant alternatives, and subcutaneous injudicious instead of intravenous administration has introduced the market for these medications to convenient long term-use type of medication. Growing trend of personalized medication is also among the critical factors that help propel the market in the anticoagulant, as physicians spend their time searching for the best medication that will meet individual patients’ needs and genetic makeup.
Anticoagulant Market Trend Analysis:
Shift Toward Direct Oral Anticoagulants (DOACs)
- A major trend in consumption, which remains a key driver of the anticoagulant market, is the shift from best-selling VKAs, including warfarin to novel DOACs among them are apixaban, rivaroxaban, edoxaban, and dabigatran. Some advantages of DOACs are lack of need for fixed dose, no necessity in daily control of blood coagulation indicators and fewer dietary constrains, which are important for VKAs’ adherence by the patients. The ease and flexibility of use of DOACs have made them a favourite amongst users and physicians alike. This in return has informed an appreciable transition to these newer therapies in dealing with situations like atrial fibrillation, DVT, and pulmonary embolism.
- Aside from simple dosing regimens, it has been found that DOACs had a more predictable anticoagulation profile that can further lower the risk of bleeding than warfarin. This better safety profile has made it possible for them to be used in the market and as continued clinical trials make it evident, they are effective and reliable. As more and more clear-cut benefits of DOACs are identified, these drugs will remain the main players on the market of anticoagulants, defining the trends in the management of thromboembolic disorders in the coming years.
Emerging Markets and Aging Population
- Market emergence in the Asia-Pacific region, Latin America and parts of Africa remains to be one of the biggest opportunities for the growth of the anticoagulant market. They are some of the areas where healthcare facilities are being developed and stretched to expand access to modern medicine even all over the world anticoagulants. As the health care system in these countries progresses, there is a growing concern in the use of anticoagulant therapies owing to a growing prevalence of chronic diseases such as cardiovascular diseases. This is further driven by the growth of public health opportunities concerning access to key medicines within several markets that greatly favour the use of anticoagulants.
- The other promising chance is the increasing global population’s aging level, particularly in developed areas. Atrial fibrillation and deep vein thrombosis – thromboembolic disorders that are prevalent in elderly people – increase the need for anticoagulant therapy, classes of drugs for which are among the most prescribed worldwide. The increase in the elderly population worldwide, and the developed economy in particular is presumed to increase the demand for anticoagulants. This demographic shift, along with the growth in knowledge and understanding of the anticoagulant therapies and their advantages, creates a suited setting for market penetration and new patient populations for the drug manufactures to break into regions that may not have been as explored as before. Altogether these factors are establishing very favourable pattern for the development of the anticoagulant market in the future years.
Anticoagulant Market Segment Analysis:
Anticoagulant Market is Segmented on the basis of by Drug Class, Application, End User, and Region.
By Drug Class, Vitamin K Antagonists (VKAs) segment is expected to dominate the market during the forecast period
- The anticoagulant market can be majorly categorized based on classes of drugs, of which there exist several drugs with varied classification in this category. For decades, VKAs, including warfarin, were the main therapy to prevent formation of blood clots through blocking the action of vitamin K, an essential element in the formation of clotting factors. Therefore, the use of the direct oral anticoagulant (DOACs) such as apixaban, rivaroxaban and dabigatran is becoming more frequent regarding the fixed doses and lack of need for frequent monitoring. Another big class is Low Molecular Weight Heparins (LMWH) like enoxaparin which gives a more predictable anticoagulation and is widely used in hospital to prevent and treat DVT & PE.
- Among them UFH is administered for more acute conditions with the probability of variability in the level of anticoagulation. Dabigatran and derivatives act at thrombin level to inhibit clot formation while rivaroxaban, apixaban and similar drugs inhibit the enzyme factor XA that is essential to formation of the clot. analysis of different drug classes indicated that different drug classes present certain advantages and limitations in terms of their application in different clinical situations, and the evident growth of new agents such as DOACs and Factor Xa inhibitors due to their convenience and lower bleeding profile.
By Application, Atrial Fibrillation (AF) segment expected to held the largest share
- The anticoagulant market is heavily influenced by its usage in treatable thromboembolic disorders. Another important coordinated condition is Atrial Fibrillation (AF) – a group of patients with AF is major for anticoagulants, because patients with AF have increased risk of blood clotting and stroke. These patients require anticoagulants for decreasing the risk of stroke and embolism in their bodies. Other Key area that Fondaparinux can be used is in the treatment/prevention of deep vein thrombosis, where clots form in the deep veins – mostly in the lower limbs. In the absence of treatment, the DVT can cause serious complications such as pulmonary embolism. Anticoagulants can be used to lessen the formation and growth of clots to better the state of affairs of a patient.
- Pulmonary embolism (PE) is the other important area that anticoagulants are utilised because it happens when a clot forms in the arteries and veins of the lungs, fully or partly blocking blood flow which is fatal. Anticoagulants can be prescribed for the treatment and also as prophylaxis of PE. Anticoagulation Therapy is related to these conditions primarily in patients who have AF or who have a history of DVT or PE since they named can PT and APTT and would prevent future strokes. Also, anticoagulants are used in Other Thromboembolic Disorders Anticoagulants including arterial thrombosis and thrombophilia. A consistently increasing incidence of such conditions, particularly in elderly patients, is the most significant factor influencing the market for anticoagulants.
Anticoagulant Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
It is forecasted that North America especially United States has dominated the market of anticoagulant and it will occupied a large proportion in the international market. The leading position of the General can be explained by the high incidence of cardiovascular diseases, first of all, atrial fibrillation, which increase the need for anticoagulant treatments. Also, the emerging number of people of older age in North America increases the demand for anticoagulant therapy for thromboembolic diseases. Owning well-developed healthcare systems, the region has an opportunity to get acquainted with the newest types of anticoagulation products, including DOACs, which have created a lot of interest due to their safety profiles and convenience.
- The complimentary factors which include North America’s well-developed, near universal healthcare coverage and major pharmaceutical firms keep on dominating the market. They keep the patients in the region better covered with the commonly known anticoagulant drugs and the newer inventions as well. More capital spending is assigned to research and development by top drug makers that underpins the region’s competitive standing. North America alone is forecast to occupy more than 40% of the global anticoagulant market by 2023 and this position is expected to improve as the requirements for these therapies are projected to rise, because of the ageing population and the increasing prevalence of cardiovascular diseases.
Active Key Players in the Anticoagulant Market:
-
Abbott Laboratories (USA)
- Amgen Inc. (USA)
- Bayer AG (Germany)
- Bristol-Myers Squibb (USA)
- Boehringer Ingelheim (Germany)
- Daiichi Sankyo (Japan)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- GSK plc (UK)
- Johnson & Johnson (USA)
- Merck & Co., Inc. (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Other Active Players
|
Anticoagulant Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 42.92 Billion |
|
Forecast Period 2024-32 CAGR: |
9.50 % |
Market Size in 2032: |
USD 97.14 Billion |
|
Segments Covered: |
By Drug class |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Anticoagulant Market by drug class
4.1 Anticoagulant Market Snapshot and Growth Engine
4.2 Anticoagulant Market Overview
4.3 Vitamin K Antagonists (VKAs)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Vitamin K Antagonists (VKAs): Geographic Segmentation Analysis
4.4 Direct Oral Anticoagulants (DOACs)
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Direct Oral Anticoagulants (DOACs): Geographic Segmentation Analysis
4.5 Low Molecular Weight Heparins (LMWH)
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Low Molecular Weight Heparins (LMWH): Geographic Segmentation Analysis
4.6 Unfractionated Heparin (UFH)
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Unfractionated Heparin (UFH): Geographic Segmentation Analysis
4.7 Direct Thrombin Inhibitors
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Direct Thrombin Inhibitors: Geographic Segmentation Analysis
4.8 Factor Xa Inhibitors
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Factor Xa Inhibitors: Geographic Segmentation Analysis
Chapter 5: Anticoagulant Market by Application
5.1 Anticoagulant Market Snapshot and Growth Engine
5.2 Anticoagulant Market Overview
5.3 Atrial Fibrillation
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Atrial Fibrillation: Geographic Segmentation Analysis
5.4 Deep Vein Thrombosis (DVT)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Deep Vein Thrombosis (DVT): Geographic Segmentation Analysis
5.5 Pulmonary Embolism (PE)
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Pulmonary Embolism (PE): Geographic Segmentation Analysis
5.6 Stroke Prevention
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Stroke Prevention: Geographic Segmentation Analysis
5.7 Other Thromboembolic Disorders
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Other Thromboembolic Disorders: Geographic Segmentation Analysis
Chapter 6: Anticoagulant Market by End User
6.1 Anticoagulant Market Snapshot and Growth Engine
6.2 Anticoagulant Market Overview
6.3 (Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 (Hospitals: Geographic Segmentation Analysis
6.4 Clinics
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinics: Geographic Segmentation Analysis
6.5 Homecare Settings
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Homecare Settings: Geographic Segmentation Analysis
6.6 Ambulatory Surgical Centers
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Ambulatory Surgical Centers: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Anticoagulant Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBOTT LABORATORIES
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 BAYER AG
7.4 BOEHRINGER INGELHEIM
7.5 BRISTOL-MYERS SQUIBB
7.6 MERCK & CO
7.7 OTHER ACTIVE PLAYERS
Chapter 8: Global Anticoagulant Market By Region
8.1 Overview
8.2. North America Anticoagulant Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By drug class
8.2.4.1 Vitamin K Antagonists (VKAs)
8.2.4.2 Direct Oral Anticoagulants (DOACs)
8.2.4.3 Low Molecular Weight Heparins (LMWH)
8.2.4.4 Unfractionated Heparin (UFH)
8.2.4.5 Direct Thrombin Inhibitors
8.2.4.6 Factor Xa Inhibitors
8.2.5 Historic and Forecasted Market Size By Application
8.2.5.1 Atrial Fibrillation
8.2.5.2 Deep Vein Thrombosis (DVT)
8.2.5.3 Pulmonary Embolism (PE)
8.2.5.4 Stroke Prevention
8.2.5.5 Other Thromboembolic Disorders
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 (Hospitals
8.2.6.2 Clinics
8.2.6.3 Homecare Settings
8.2.6.4 Ambulatory Surgical Centers
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Anticoagulant Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By drug class
8.3.4.1 Vitamin K Antagonists (VKAs)
8.3.4.2 Direct Oral Anticoagulants (DOACs)
8.3.4.3 Low Molecular Weight Heparins (LMWH)
8.3.4.4 Unfractionated Heparin (UFH)
8.3.4.5 Direct Thrombin Inhibitors
8.3.4.6 Factor Xa Inhibitors
8.3.5 Historic and Forecasted Market Size By Application
8.3.5.1 Atrial Fibrillation
8.3.5.2 Deep Vein Thrombosis (DVT)
8.3.5.3 Pulmonary Embolism (PE)
8.3.5.4 Stroke Prevention
8.3.5.5 Other Thromboembolic Disorders
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 (Hospitals
8.3.6.2 Clinics
8.3.6.3 Homecare Settings
8.3.6.4 Ambulatory Surgical Centers
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Anticoagulant Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By drug class
8.4.4.1 Vitamin K Antagonists (VKAs)
8.4.4.2 Direct Oral Anticoagulants (DOACs)
8.4.4.3 Low Molecular Weight Heparins (LMWH)
8.4.4.4 Unfractionated Heparin (UFH)
8.4.4.5 Direct Thrombin Inhibitors
8.4.4.6 Factor Xa Inhibitors
8.4.5 Historic and Forecasted Market Size By Application
8.4.5.1 Atrial Fibrillation
8.4.5.2 Deep Vein Thrombosis (DVT)
8.4.5.3 Pulmonary Embolism (PE)
8.4.5.4 Stroke Prevention
8.4.5.5 Other Thromboembolic Disorders
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 (Hospitals
8.4.6.2 Clinics
8.4.6.3 Homecare Settings
8.4.6.4 Ambulatory Surgical Centers
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Anticoagulant Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By drug class
8.5.4.1 Vitamin K Antagonists (VKAs)
8.5.4.2 Direct Oral Anticoagulants (DOACs)
8.5.4.3 Low Molecular Weight Heparins (LMWH)
8.5.4.4 Unfractionated Heparin (UFH)
8.5.4.5 Direct Thrombin Inhibitors
8.5.4.6 Factor Xa Inhibitors
8.5.5 Historic and Forecasted Market Size By Application
8.5.5.1 Atrial Fibrillation
8.5.5.2 Deep Vein Thrombosis (DVT)
8.5.5.3 Pulmonary Embolism (PE)
8.5.5.4 Stroke Prevention
8.5.5.5 Other Thromboembolic Disorders
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 (Hospitals
8.5.6.2 Clinics
8.5.6.3 Homecare Settings
8.5.6.4 Ambulatory Surgical Centers
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Anticoagulant Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By drug class
8.6.4.1 Vitamin K Antagonists (VKAs)
8.6.4.2 Direct Oral Anticoagulants (DOACs)
8.6.4.3 Low Molecular Weight Heparins (LMWH)
8.6.4.4 Unfractionated Heparin (UFH)
8.6.4.5 Direct Thrombin Inhibitors
8.6.4.6 Factor Xa Inhibitors
8.6.5 Historic and Forecasted Market Size By Application
8.6.5.1 Atrial Fibrillation
8.6.5.2 Deep Vein Thrombosis (DVT)
8.6.5.3 Pulmonary Embolism (PE)
8.6.5.4 Stroke Prevention
8.6.5.5 Other Thromboembolic Disorders
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 (Hospitals
8.6.6.2 Clinics
8.6.6.3 Homecare Settings
8.6.6.4 Ambulatory Surgical Centers
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Anticoagulant Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By drug class
8.7.4.1 Vitamin K Antagonists (VKAs)
8.7.4.2 Direct Oral Anticoagulants (DOACs)
8.7.4.3 Low Molecular Weight Heparins (LMWH)
8.7.4.4 Unfractionated Heparin (UFH)
8.7.4.5 Direct Thrombin Inhibitors
8.7.4.6 Factor Xa Inhibitors
8.7.5 Historic and Forecasted Market Size By Application
8.7.5.1 Atrial Fibrillation
8.7.5.2 Deep Vein Thrombosis (DVT)
8.7.5.3 Pulmonary Embolism (PE)
8.7.5.4 Stroke Prevention
8.7.5.5 Other Thromboembolic Disorders
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 (Hospitals
8.7.6.2 Clinics
8.7.6.3 Homecare Settings
8.7.6.4 Ambulatory Surgical Centers
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Anticoagulant Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 42.92 Billion |
|
Forecast Period 2024-32 CAGR: |
9.50 % |
Market Size in 2032: |
USD 97.14 Billion |
|
Segments Covered: |
By Drug class |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
